[go: up one dir, main page]

MA27682A1 - Compositions de valdecoxib a delitement intra-oral - Google Patents

Compositions de valdecoxib a delitement intra-oral

Info

Publication number
MA27682A1
MA27682A1 MA27586A MA27586A MA27682A1 MA 27682 A1 MA27682 A1 MA 27682A1 MA 27586 A MA27586 A MA 27586A MA 27586 A MA27586 A MA 27586A MA 27682 A1 MA27682 A1 MA 27682A1
Authority
MA
Morocco
Prior art keywords
valdecoxib
compositions
intraoral delivery
valdecoxib compositions
oral
Prior art date
Application number
MA27586A
Other languages
English (en)
Inventor
Blake C Ludwig
Uday J Shah
Trang T Le
Joseph P Reo
Ken Yamamoto
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MA27682A1 publication Critical patent/MA27682A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Société dite : PHARMACIA CORPORATION REVENDICATION DE PRIORITES US 26 Septembre 2001 60/325,356 Compositions de valdécoxib à délitement intra-oral Des comprimés de valdécoxib à délitement oral, fondant rapidement, et des procédés pour la préparation de ces formes posologiques sont proposés. Les compositions sont utiles dans le traitement ou la prophylaxie de troubles et d'affections à médiation par la cyclo-oxygénase-2.
MA27586A 2001-09-26 2004-03-24 Compositions de valdecoxib a delitement intra-oral MA27682A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
MA27682A1 true MA27682A1 (fr) 2006-01-02

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
MA27587A MA27542A1 (fr) 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique.
MA27586A MA27682A1 (fr) 2001-09-26 2004-03-24 Compositions de valdecoxib a delitement intra-oral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA27587A MA27542A1 (fr) 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Country Status (25)

Country Link
US (1) US20030181501A1 (fr)
EP (2) EP1490035A1 (fr)
JP (2) JP2005506987A (fr)
KR (2) KR20040058189A (fr)
CN (2) CN1703203A (fr)
AP (2) AP2004002999A0 (fr)
AR (1) AR037239A1 (fr)
BR (2) BR0212861A (fr)
CA (2) CA2461044A1 (fr)
CO (2) CO5570659A2 (fr)
EA (2) EA200400352A1 (fr)
EC (1) ECSP045029A (fr)
GE (1) GEP20063856B (fr)
HK (1) HK1079988A1 (fr)
IL (2) IL160855A0 (fr)
IS (2) IS7177A (fr)
MA (2) MA27542A1 (fr)
MX (2) MXPA04002652A (fr)
NO (2) NO20041258L (fr)
OA (2) OA13060A (fr)
PL (2) PL369298A1 (fr)
TN (2) TNSN04045A1 (fr)
WO (2) WO2003026697A2 (fr)
YU (1) YU34804A (fr)
ZA (2) ZA200401953B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (fr) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Compositions pharmaceutiques comprenant un ether et un inhibiteur selectif de la cyclooxygenase-2 et leur utilisations
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
WO2006016602A1 (fr) * 2004-08-10 2006-02-16 Ajinomoto Co., Inc. Préparation contenant du natéglinide dont l'amertume a été réduite
JP5209876B2 (ja) * 2004-12-28 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 速崩壊性錠剤及びその製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
KR20080080318A (ko) * 2005-12-20 2008-09-03 에자이 알앤드디 매니지먼트 가부시키가이샤 지용성 약물을 함유하는 구강내 속붕정
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) * 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007087188A2 (fr) * 2006-01-20 2007-08-02 Merck & Co., Inc. Comprimes et granules au gout masque
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
CA2687124A1 (fr) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Formulations de doxepine a faible dose, incluant des formulations buccales, sublinguales et a dissolution rapide, et leurs utilisations pour traiter l'insomnie
ES2646112T3 (es) * 2007-06-06 2017-12-12 Basf Se Formulación farmacéutica para la fabricación de comprimidos que se desintegran rápidamente
ES2639130T3 (es) * 2007-06-06 2017-10-25 Basf Se Formulación farmacéutica para la fabricación de comprimidos de rápida desintegración
CA2688389A1 (fr) * 2007-06-06 2008-12-11 Basf Se Preparation pharmaceutique pour produire des comprimes a delitement rapide
JP2010529073A (ja) * 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
JP5632284B2 (ja) * 2007-08-07 2014-11-26 エーセルアールエックス ファーマシューティカルズ， インコーポレイテッド 経口経粘膜剤形を使用する処置時の鎮静および無痛のための組成物および方法
WO2009118589A2 (fr) 2008-03-24 2009-10-01 Wockhardt Research Centre Compositions orodispersibles de rhéine ou de diacéréine
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
KR101753411B1 (ko) * 2008-11-25 2017-07-03 미쓰비시 타나베 파마 코퍼레이션 구강 내 속붕괴성정 및 그의 제조 방법
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
CA2178686A1 (fr) * 1995-06-13 1996-12-14 Leslie G. Humber Formulations orales de s(+)-etodolac
US5954204A (en) * 1995-10-20 1999-09-21 Phatmacia & Upjohn Company Blister package
WO1997044028A1 (fr) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions pour traitement journalier monodose de maladies a mediateur cyclooxygenase-2
EP0863134A1 (fr) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
KR100645866B1 (ko) * 1999-12-08 2006-11-15 파마시아 코포레이션 발데콕시브 조성물
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
WO2002015884A2 (fr) * 2000-08-18 2002-02-28 Pharmacia Corporation Preparation orale a desintegration rapide d'un inhibiteur de la cyclooxygenase-2
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物

Also Published As

Publication number Publication date
TNSN04045A1 (fr) 2006-06-01
MXPA04002798A (es) 2004-07-05
WO2003026697A3 (fr) 2003-07-03
EA200400352A1 (ru) 2004-12-30
ZA200402364B (en) 2005-01-13
JP2005512964A (ja) 2005-05-12
CA2461044A1 (fr) 2003-04-03
BR0212861A (pt) 2004-10-05
CO5570684A2 (es) 2005-10-31
NO20041532L (no) 2004-04-15
CN1703203A (zh) 2005-11-30
GEP20063856B (en) 2006-06-26
WO2003026623A8 (fr) 2004-09-30
NO20041258L (no) 2003-03-27
WO2003026623A1 (fr) 2003-04-03
PL369298A1 (en) 2005-04-18
PL369297A1 (en) 2005-04-18
JP2005506987A (ja) 2005-03-10
CO5570659A2 (es) 2005-10-31
IS7178A (is) 2004-03-11
EA200400357A1 (ru) 2004-08-26
IS7177A (is) 2004-03-11
WO2003026697A2 (fr) 2003-04-03
IL160848A0 (en) 2004-08-31
CN1633281A (zh) 2005-06-29
MXPA04002652A (es) 2004-06-07
EP1429736A2 (fr) 2004-06-23
HK1079988A1 (zh) 2006-04-21
OA12707A (en) 2006-06-26
EP1490035A1 (fr) 2004-12-29
MA27542A1 (fr) 2005-10-03
BR0212778A (pt) 2004-12-07
IL160855A0 (en) 2004-08-31
US20030181501A1 (en) 2003-09-25
KR20040058189A (ko) 2004-07-03
TNSN04047A1 (fr) 2006-06-01
ZA200401953B (en) 2005-05-09
AP2004002998A0 (en) 2004-03-31
KR20040044990A (ko) 2004-05-31
AP2004002999A0 (en) 2004-03-31
OA13060A (en) 2006-11-10
YU34804A (sh) 2006-08-17
AR037239A1 (es) 2004-11-03
CA2461630A1 (fr) 2003-04-03
ECSP045029A (es) 2004-04-28

Similar Documents

Publication Publication Date Title
MA27682A1 (fr) Compositions de valdecoxib a delitement intra-oral
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
TNSN99223A1 (fr) Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et procedes de traitement les utilisant
BR0011867A (pt) Preparação farmacêutica de levodopa/carbidopa/entacapona
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
WO2003047519A3 (fr) Composition pharmaceutique pour comprime annulaire compresse et comprime triture moule pour administration intra-orale et par voie buccale
TWI265808B (en) Valdecoxib compositions
BR1100625A (pt) Composição farmacêutica sublingual ou bucal, e, utilização do trans-5-cloro-2-metil-2,3,3a, 12b-tetraido-1h-dibenz[2,3:6,7]oxepino [4,5-c]pirrol
CA2427227A1 (fr) Compose de lactam
KR970061244A (ko) 치매 치료용 약학 조성물
EP1539136A4 (fr) Composes selectifs des recepteurs ppar alpha destines au traitement de la dyslipidemie et d'autres troubles lipidiques
MY129314A (en) Pharmaceutical composition comprising sumatriptan
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
BR0014979A (pt) Composição hormonal e sua utilização
SE9903995D0 (sv) New combination
BR9912588A (pt) Prevenção de recorrência de enxaqueca
RU2001124802A (ru) Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
MA27543A1 (fr) Compositions de valdecoxib a delitement intra-oral preparees par un procede de sechage par pulverisation.
MA27136A1 (fr) Association nouvelle.
MA26698A1 (fr) Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation
FR2774289B1 (fr) Medicament pour le traitement des dereglements de l'apoptose
HUP0300717A2 (hu) Mirtazapint és paracetamolt vagy nem szteroid gyulladáscsökkentő gyógyszert tartalmazó gyógyszerkombináció fejfájás kezelésére
Babaloo et al. Comparison of analgesic effects of novafen and ibuprofen after periodontal surgeries
FR2759587B1 (fr) Composition pharmaceutique pour l'administration buccale de thiocolchicoside